New combo tackles Drug-Resistant lung cancer
NCT ID NCT05773092
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 20 times
Summary
This study tests whether adding a chemotherapy drug called S-1 to the targeted therapy osimertinib can shrink tumors in people with a specific type of lung cancer (EGFR mutant NSCLC) that has stopped responding to treatment. About 30 adults with advanced lung cancer will receive the combination. The main goal is to see how many patients have their tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center Singapore
Singapore, 169690, Singapore
Conditions
Explore the condition pages connected to this study.